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Introduction: Off-label drug use refers to drug use beyond the specifications authorized for marketing. Eltrombopag is a
new thrombopoietin receptor agonist which was used successfully in this critical case of thrombocytopenia associated
with hepatitis C infection before it became an approved drug for such cases.
Case presentation: A 56-year-old Kuwaiti woman with hepatitis C virus infection was treated with pegylated interferon
α-2a and ribavirin, laboratory test results prior to therapy were within normal values. After 4 weeks of that treatment, she
developed neutropenia and severe thrombocytopenia. Her hepatitis C virus treatment was stopped for many years until
eltrombopag was used as an off-label drug with an episode of severe thrombocytopenia. Her platelets count returned to
normal level when triple therapy for hepatitis C virus was used successfully.
Conclusions: An off-label drug should be used only when it is the best available drug, based on evidence from on-going
multicenter trials. It could be life saving for some patients in critical situations. However, clinical use of eltrombopag later
confirmed that it is a safe and effective drug for immune thrombocytopenic purpura or thrombocytopenia associated
with hepatitis C virus infection.
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Hepatitis C virus (HCV) infection is known to result in
thrombocytopenia, even in the absence of overt hepatic
disease. This infection is considered a marker for sever-
ity of liver disease and may sometimes be the only
manifestation of viral hepatitis. It is estimated that 160
million individuals worldwide have chronic HCV infec-
tion. Moreover, this infection has been associated with
an increased risk of developing chronic immune throm-
bocytopenic purpura (ITP) [1]. HCV infection-induced
thrombocytopenia has an underlying autoimmune
mechanism similar to that of ITP. The virus binds to
thrombocytes, resulting in the production of autoanti-
bodies against thrombocyte membrane antigens. Over
90% of patients with chronic HCV infection develop
high levels of immunoglobulin (Ig)G associated throm-
bocytes called platelet-associated IgG (PAIgG) [2]. The* Correspondence: Cbc9@hotmail.com
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thrombocyte membrane surface and label them for
autoimmune destruction in the reticuloendothelial sys-
tem [3]. High PAIgG levels are directly related with liver
disease severity, suggesting that chronic HCV infection
is associated with major changes in the immune system.
Patients who underwent interferon-α and ribavirin
therapy had significant adverse effects, including body
aches, malaise in 60%, fever in 35%, anaphylaxis in 2%,
thrombocytopenia in 15%, and granulocytopenia in
26% [4].
Off-label drug use (OLDU) refers to drug use for
unlicensed indications, in terms of doses, preparation,
patient population, or route of administration, beyond
the specifications authorized for marketing [5]. In the
USA, OLDU implies the prescription of a drug that is
not specified in the labeling approved by the US Food
and Drug Administration (FDA) [6].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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In 2002, a 56-year-old Kuwaiti woman without a history
of blood transfusion was diagnosed with chronic hepa-
titis C. She may have contracted the viral infection while
administering insulin injections to a friend with chronic
HCV. Virology studies revealed HCV genotype 1 infection.
Polymerase chain reaction indicated an HCV-ribonucleic
acid (RNA) viral load by TaqMan® of 785,000IU/mL (lower
limit >15IU/mL). The histologic sections at that time
showed the overall architecture was preserved. There was a
portal and periportal fibrosis with occasional bridging. Hist-
ology also showed mild to moderate portal inflammation,
composed of mostly small lymphocytes, with focal inter-
face hepatitis. Few plasma cells and histiocytes were noted
with mild to moderate lobular inflammation and scattered
acidophil bodies and minimal macrovesicular steatosis.
There was no significant cholestasis, Mallory hyaline, bal-
looning degeneration or intranuclear/cytoplasmic inclu-
sions. Her central veins were unremarkable. Iron stain
highlighted a few Kupffer cells with increase iron storage.
Periodic acid–Schiff diastase stain was negative for intra-
cytoplasmic globules (Figure 1).
In 2003, she was treated with pegylated interferon α-
2a (Pegasys®, Hoffmann-La Roche Inc., NJ, USA) 180μg
per week and ribavirin 1000mg daily. Laboratory test re-
sults prior to the therapy were as follows with the mini-
mum and maximum normal values: white blood cell
(WBC) count, 4 (4 to 10×109/L); hemoglobin (Hb) level,
14.1g/L (12.0 to 15.0g/L); platelet count, 167×109/L (150
to 410×109/L); international normalized ratio, 1.1; total
protein level, 72g/L (61 to 79g/L); albumin level, 42g/L
(35 to 48g/L); alkaline phosphatase level, 66IU/L (42 to
98IU/L); alanine transaminase (ALT), 308IU/L (10 to
60IU/L); aspartate aminotransferase (AST) level, 174IU/
L (10 to 42IU/L); and thyroid-stimulating hormone,
4.01mIU/L (0.43 to 4.1mIU/L). Her serum was negativeFigure 1 Inflamed portal tract area with interface hepatitis,
shows inflammatory cells beyond the limiting plate.for antinuclear antibodies, antimitochondrial antibodies
and antismooth muscle antibodies. A quantitative assay
indicated normal serum Ig levels. An abdominal ultra-
sound did not indicate any abnormality.
After 4 weeks of treatment with interferon, she developed
neutropenia (WBC count, 2.9×109/L). She was then admin-
istered 300μg of the granulocyte colony-stimulating factor
Neupogen® (filgrastim; Amgen Inc., CA, USA). She also de-
veloped severe thrombocytopenia (platelet count, 5×109/L)
and underwent transfusion with 19 platelet units. A bone
marrow biopsy revealed the presence of normal cellularity
and normal differentiation of the three cell lineages, indicat-
ing neutropenia and thrombocytopenia due to peripheral
destruction. Intravenous Ig 0.4g/kg daily was administered
for 5 days. There was good response to the treatment, and
her platelet count increased to 104×109/L. Because of se-
vere thrombocytopenia, she was considered unsuitable for
further interferon therapy. Treatment with peginterferon
had probably caused the thrombocytopenia, and thus, treat-
ment was discontinued for approximately 7 years owing to
the risk of thrombocytopenia recurrence. Between 2004
and 2010, her platelet count oscillated between 50 and
100×109/L.
In late 2010, she again presented with severe and
progressive thrombocytopenia. At that time, her plate-
let count dropped from 72 to 17×109/L throughout the
year. Intravenous Ig was administered without ad-
equate response: platelets only increased to 31×109/L
and then dropped to 6×109/L after 7 days of treatment.
She was referred again to the Hematology Outpatient
Consultation Department. Eltrombopag 50mg daily
was administered off label because intravenous Ig be-
came progressively less effective in this case. After 10
days of treatment, there was a very good response (Figure 2);
her platelet count increased to 250×109/L. The dose was
then reduced to 25mg daily. After 3 months of normal
platelet count by continuous administration of eltrombopag
25mg daily, the hepatologist considered the patient eligible
for HCV infection treatment.
In 2011, an HCV-RNA viral load by TaqMan® of
3,141,000IU/mL was indicated; she received triple HCV
infection therapy (interferon, ribavirin, and telaprevir).
Her platelet count did not reduce while she was on
eltrombopag as well as the triple therapy. However, after
the triple therapy, she had serious complications and
presented hemolytic anemia and urticaria. One month
later, she developed severe pneumonia with oxygen
desaturation and required mechanic ventilation in our
intensive care unit for 7 days where eltrombopag was
stopped. During this period, her platelet count decreased
once again to 76×109/L. However, once eltrombopag was
resumed, her normal platelet count was re-established to
normal values. She fully recovered from this complica-
tion and is currently leading a normal life with normal
Figure 2 Platelets levels during the treatment course.
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WBC, platelet, ALT, AST, gamma-glutamyltransferase and
so on). Even after 3.5 years, she continues to receive
eltrombopag treatment. In 2013, her platelet count reduced
to 67×109/L owing to treatment cessation for 22 Days; her
platelet count returned to 131×109/L once she resumed
taking eltrombopag 25mg daily (Figure 2). On May 2013
HCV-RNA viral load by TaqMan® was not detected.
Discussion
Chronic HCV may be accompanied by variable levels of
thrombocytopenia caused by different mechanisms: cen-
tral and peripheral autoimmune mechanisms or drug-
induced thrombocytopenia. An autoimmune mechanism
was found in 85% of the cases. HCV infection can
directly suppress megakaryocyte production. Interferon
treatment also has a direct myelosuppressive effect that
could lead to thrombocytopenia [7]. Patients are consid-
ered eligible for HCV infection treatment if their platelet
count is above 90×109/L [8]. In December 2012, eltrom-
bopag was approved by the US FDA for treatment of
HCV infection-related thrombocytopenia. It is the first
drug approved for ITP treatment in patients who are
refractory to other treatments (for example, corticosteroids,
Igs) [9]. Eltrombopag is also the first orally bioavailable
drug in its class and is a thrombopoietin receptor agonist
that induces increased proliferation and differentiation of
human bone marrow progenitor cells into megakaryocytes
and increased platelet production in the circulation. The
development of a targeted thrombopoietin receptor agonist
has great implications for the therapy of patients with dis-
eases associated with decreased platelets [10]. Eltrombopag
is found in medical trials to provide clinical benefits in
other conditions in which thrombocytopenia can occur,such as postchemotherapy and myelodysplastic syndrome
[11]. Our patient did not refer or present any treatment re-
lated adverse effects on hematology, coagulation, or clinical
chemistry parameters during her treatment with eltrombo-
pag. Reportedly, the adverse effects of eltrombopag are mild
and only seen in a few patients; these effects include head-
ache, nasopharyngitis, upper respiratory tract infection, fa-
tigue, arthralgia, diarrhea, nausea, back pain, and urinary
tract infection [12]. OLDU based on evidence obtained
from controlled research trials is a useful medical tool. This
case is an example of life-saving treatment with OLDU, and
this drug was approved after approximately 2 years for
thrombocytopenia due to chronic HCV infection [13].
Currently, eltrombopag is in use in adult patients with
HCV with chronic HCV infection for the treatment of
thrombocytopenia when the degree of thrombocytopenia
severity should be considered while maintaining optimal
interferon-based therapy [14]. Platelet counts with eltrom-
bopag treatment should be adjusted to maintain a platelets
count of around 100×109/L, to avoid the risk of portal vein
thrombosis in a patient with liver disease [15].
Conclusions
OLDU could be life saving for some patients in critical
situations. Its use must be based on evidence from on-
going multicenter trials. OLDU must be the best avail-
able drug to be used. However, not all off-label drugs
become approved but the new thrombopoietin receptor
agonist eltrombopag became an approved effective drug
for thrombocytopenia associated with HCV.
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